Epidemiology Status Of Liver Cancer

According to statistics, in 2018 there were more than 390,000 new cases of liver cancer in China, ranking third among all newly diagnosed malignant tumors. In the same year, over 360,000 people died from liver cancer, making it the third leading cause of cancer-related deaths. Data shows that in 2018, nearly 47% of global liver cancer cases occurred in China, establishing the country as the most prevalent region for this disease.

The high incidence of liver cancer in China is closely linked to the widespread prevalence of hepatitis B. At its peak, the hepatitis B positivity rate in China reached about 10%. Although this rate has decreased to approximately 7%-8% today, due to China's large population base, the number of liver cancer patients in the country remains significantly higher than in any other part of the world.

Given these statistics, effective treatment and prevention strategies for liver cancer are critically important for public health in China. Addressing the root causes, such as hepatitis B infection, could play a key role in reducing the burden of this deadly disease. Early detection, vaccination programs, and improved healthcare access are essential components of a comprehensive approach to combat liver cancer.

In conclusion, liver cancer continues to pose a major health challenge in China. Understanding its epidemiological patterns helps guide targeted interventions and resource allocation to reduce mortality rates and improve patient outcomes.